These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25367863)

  • 1. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
    Kelly E; Lu CY; Albertini S; Vitry A
    J Clin Pharm Ther; 2015 Feb; 40(1):76-82. PubMed ID: 25367863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia.
    Vitry AI; Thai LP; Lu CY
    Intern Med J; 2011 Feb; 41(2):162-6. PubMed ID: 20646097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
    Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
    PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
    Clemons M; Coleman RE; Verma S
    Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advancement in endocrine therapy for breast cancer].
    Yang MT; Lian ZQ
    Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G; Verma S; Trudeau M
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    Abrial C; Leheurteur M; Cabrespine A; Mouret-Reynier MA; Durando X; Ferriere JP; Kwiatkowski F; Penault-Llorca F; Cure H; Chollet P
    Oncol Res; 2006; 15(9):431-9. PubMed ID: 16555549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.